Predictive factors in HER2-positive early breast cancer: endogenous HER2-specific immune response as an early predictive marker for pathologic complete response and disease-free survival

Ähnliche Einträge

• Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis
  von: Swain, Sandra M., et al.
  Veröffentlicht: (2022)
• Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
  von: Häberle, Lothar, et al.
  Veröffentlicht: (2025)
• Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
  von: Loibl, Sibylle, et al.
  Veröffentlicht: (2017)
• The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: a translational research project of a prospective randomized phase III trial
  von: Jäger, Bernadette, et al.
  Veröffentlicht: (2017)
• Therapy standards in HER2-positive breast cancer
  von: Gluz, Oleg, et al.
  Veröffentlicht: (2016)